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Abstract
A key characteristic of cancer cells is the ability to switch from a predominantly oxidative metabolism
to glycolysis and the production of lactate even when oxygen is plentiful. This metabolic switch, known
as the Warburg effect, was ﬁrst described in the 1920s, and has fascinated and puzzled researchers ever
since. However, a dramatic increase in glycolysis in the presence of oxygen is one of the hallmarks of the
development of the early mammalian embryo; a metabolic switch with many parallels to the Warburg
effect of cancers. The present review provides a brief overview of this and other similarities between the
metabolism in tumours and early embryos and proposes whether knowledge of early embryo metabolism
can help us to understand metabolic regulation in cancer cells.
Introduction
The origins of the study of cancer cell metabolism can be
traced back to the work of Warburg in the 1920s, who
first showed that many tumours increase the consumption
of glucose and production of lactate in the presence of
oxygen (summarized by Warburg [1]). Although the cells
of most tissues can switch from mitochondrial oxidative
phosphorylation to glycolytic production of ATP under
hypoxic conditions, cancer cells appear to adopt this
metabolic phenotype as part of their normal function and in
the presence of oxygen. This ‘aerobic glycolysis’ has been
observed in tumours in vivo, and is used as a diagnostic
tool [2]. However, cancer cells are not the only cells to
be characterized by high aerobic glycolysis; such an effect
has been described as the metabolic phenotype of rapidly
proliferating cells generally [3].
Interestingly, aerobic glycolysis occurs in the early
preimplantation mammalian embryo, an observation first
hinted at by the work of Fridhandler [4]. Moreover, it is now
apparent that this is not the only metabolic feature that is
common to cancers and early embryos. In the present review,
we provide an overview of key metabolic strategies of the
early embryo as it undergoes preimplantation development,
with emphasis on glucose, amino acids and fatty acids, and
highlight some of the parallels with the superficial metabolic
hallmarks of cancer progression.
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Early embryo development and
metabolism
During mammalian preimplantation development, the fer-
tilized egg, or zygote, undergoes a series of mitotic divisions
until it ultimately forms a blastocyst, a key developmental end
point after which implantation occurs (Figure 1). Formation
of the blastocyst is a dynamic period of development,
characterized by an increase in ATP demand and met
primarily through oxidative metabolism [5–7], which is
relatively low during cleavage development, before rising
2–4-fold during the formation of the blastocyst.
The study of substrate utilization to satisfy ATP demand
by early embryos has traditionally been driven by the desire
to define the ‘requirements’ for embryos to be grown in vitro,
with a view to improving success rates in clinical IVF (in vitro
fertilization) [8]. A complementary aim to this has been
attempts to discover non-invasive biomarkers of embryo
viability [9,10] and studies in this area have provided a good
understanding of how the early embryo uses a number of
key metabolic substrates, such as glucose, pyruvate, lactate,
amino acids and fatty acids.
Glucose metabolism in cancers and early
embryos
Cancers
Aerobic glycoloysis in tumours occurs despite vasculariza-
tion or ready access to oxygen as is the case for haematological
cancers. The biological explanation and mechanism under-
lying aerobic glycolysis are unclear. Although a number of
cancers exhibit genetic defects in the mitochondrial proteins
in the oxidative phosphorylation chain, the majority of
cancers do not, and the origins of aerobic glycolysis are likely
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Figure 1 A brief overview of preimplantation development from the one-cell zygote to the formation of a blastocyst
The fertilized zygote completes a number of mitotic divisions in a process called cleavage. With each progressive cleavage,
the embryo replicates its nuclear component and increases cell number, but distributes cytoplasm among the daughter
blastomeres, thus reducing the size of each individual cell with the net result of no overall change in total size, and
biosynthesis largely limited to the production of membranes. After eight to ten rounds of cleavage, the blastomeres are
no longer visible as individual cells as the cells compact on each other, coincident with the formation of cell–cell junctions;
at this stage, the early embryo is referred to as a morula, which subsequently forms a blastocyst. This key stage in early
development comprises the ﬁrst cellular differentiation, resulting in the TE (trophectoderm) lineage and the ICM (inner cell
mass). It is from the ICM that embryonic stem cells can be derived in vitro, whereas in situ these cells give rise to the embryo
proper. Additionally, the blastocyst marks the start of true embryonic growth, protein synthesis, mitochondrial maturation
and biogenesis and ion pumping to form the ﬂuid-ﬁlled blastocoel cavity.
to bemultifactorial [11,12]. By-products of glycolysis include
large amounts of lactate and free acid (H+ ), both of which are
toxic to normal cells. However, cancer cells appear to select
for this ability and thrive rather than undergo apoptosis. Thus
the production of lactate leads to acute and chronic local
acidosis, which may provide tumour cells with a selective
advantage over neighbouring cells, which lack mechanisms
to cope with a reduction in pH [2]. Acidification of the
local environmentmay lead to the breakdown of extracellular
matrix, disruption of gap junctions and ultimately promote
invasion and metastasis.
Embryos
Similar to the aerobic glycolysis observed in a tumour cell,
the metabolism of a blastocyst is typified by an increase
in the consumption of glucose. This has been studied most
extensively in the early embryos of mouse [6,12,13], although
it has also been reported in cow [7], pig [5,14] and human [15].
Coincidingwith the rise in glucose consumption, mammalian
blastocysts release significant quantities of lactate [6,7,14].
Glycolysis occurs at a high level (80–90%) in embryos
produced in vitro, but to a lesser extent in those produced
in vivo and flushed from the female tract (44% in mouse).
This value of glycolysis increases within 1 h to close to the
in vitro level [16], and, surprisingly, is increased in a high
oxygen environment. Taken together, this may be interpreted
that the glycolytic activity of blastocysts is independent of
oxygen levels. In this regard, the appearance of an aerobic
glycolytic phenotype as the mammalian embryo forms a
blastocyst appears to be very similar to that of tumour cells.
This notionwas recently the subject of an authoritative review
by Krisher and Prather [17]. The mammalian blastocyst must
obviously implant in the uterus for successful pregnancy,
and it is tempting to speculate that extracellular acidification
mediated by glycolytic production of lactate plays a role in
supporting this tissue implantation by the early embryo in
a manner that mirrors tumour invasion as hypothesized by
Gatenby and Gillies [2].
The idea that glycolysis increases in cancers and embryos
solely to provide ATP may be misguided since glycolytic
conversion of glucose into lactate is an inefficient way
of producing ATP compared with the complete oxidation
through the TCA (tricarboxylic acid) cycle. However,
a compelling explanation for the increased need for
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glycolysis comes from Vander Heiden et al. [3], who argue
that partitioning glucose through glycolysis may result
in an increased production of glycolytic intermediaries,
particularly glucose 6-phosphate, which can be shunted into
the PPP (pentose phosphate pathway). In both tumour cells
and early embryos, it is unlikely that the supply of substrates
forATPproductionwill be limiting; it ismuchmore probable
that demand for carbon for biosynthesis may outweigh
supply. Increased flux through the PPP may mediate this
shortfall of carbon for biosynthesis.
Cells have differential requirements for nucleic acid and
lipid precursors to support rapid proliferation [3]
and the PPP is an essential source of ribose sugars
required for nucleic acid synthesis, as well as NAD(P)H,
the reducing agent and cofactor in lipid biosynthesis.
Furthermore, NAD(P)H is necessary for maintenance of
cellular redox status by driving glutathione reductase activity
[18], which reduces GSSG back to GSH, as well as the
biosynthesis of GSH itself. GSH is ubiquitously expressed in
tissues and is the most abundant non-enzymatic antioxidant
in mammalian cells, including early embryos [19].
As described above, the developing blastocyst begins
rapid proliferation, increases protein synthesis and true
growth begins, and it is therefore likely that demand
of important biosynthetic precursors is met in part by
PPP activity. In the early embryo, Javed and Wright [20]
reported that the proportion of glucose flowing through the
PPP increases from approximately 7% during the cleavage
stage to approximately 20% in the blastocyst, indicating
the importance of this pathway in normal preimplantation
development.
Amino acids
Cancer cells
Increased glutaminolysis has been described as a metabolic
hallmark of cancer progression [21], and a simultaneous
increase in glycolysis and glutaminolysis occurs in a number
of rapidly proliferating cell types including cancer cells [22].
Glutamine is converted into glutamate by mitochondrial and
cytoplasmic glutaminase, then converted into 2-oxoglutarate
(α-ketoglutarate) catalysed by glumate dehydrogenase. 2-
Oxoglutarate feeds directly into the TCA cycle, thus is an
important cellular source of ATP, with as much as 50% of
cellular ATP produced by this mechanism in some cancers
[23]. However, similar to aerobic glycolysis, it is likely
that increased glutaminolysis in tumours and other rapidly
proliferating cells may have roles in addition to ATP supply.
A number of tumour cells overexpress cytoplasmic malic
enzyme [24] that converts malate into pyruvate, which can
be exported from mitochondria, leading to a downstream
production of NADPH required for other biosynthetic
pathways and redox regulation [23].Glutamine is a key source
of nitrogen and carbon for biosynthetic processes and also
plays an anaplerotic role in tumours, by generating citrate
to replenish carbon atoms lost from the TCA cycle to lipid
biosynthesis [25].
Early embryos
Provision of glutamine during embryo development in vitro
leads to a dramatic improvement in development [26–29].
It is consistently depleted from the culture medium of
early embryos in all species studied [10,30,31]. Interestingly,
the pattern of consumption and release of a number of
amino acids, including glutamine is predictive of embryo
viability and may well form the basis of a biomarker for the
selection of embryos for transfer in a clinical IVF setting. The
metabolic roles of glutamine in early embryonic development
include provision of ATP via conversion to 2-oxoglutarate
and oxidative metabolism [32], involvement in biosynthetic
processes [33] and an osmolyte.
The importance of glutaminolysis in early embryos and
cancer cells is one of a number of similarities in usage of
amino acids between these apparent disparate tissue types.
With regard to other amino acids, in a recent technical tour
de force, Jain et al. [34] performed a comprehensive analysis
of the consumption and release of over 200 small-molecule
metabolites by a range of cancer cell lines in vitro. The
standout observation in this work was a switch from glycine
release to glycine consumption that correlated strongly with
cancer progression. An analogous pattern has been reported
in early human embryos; those embryos that are unable to
give a pregnancy release glycine into the culture medium.
By contrast, viable embryos switch to a modest retention
of glycine. An increased requirement for glycine during
development of viable embryos and cancer progression may
stem from a need for GSH to protect against oxidative
damage. Although not the rate-limiting step, glycine is an
important precursor for the synthesis of GSH; the final step
of GSH biosynthesis is the addition of glycine to glutamyl
cysteine catalysed by GSH synthetase.
Fatty acid metabolism
Cancer cells
The role of fatty acid metabolism in cancer cells has
received very little attention, with the bulk of this limited
research focusing on de novo synthesis of fatty acids [35] in
tumorigenesis to provide the building blocks for membrane
synthesis, signal transductionmolecules and pro-tumorigenic
lipid signalling molecules. Increased fatty acid synthesis in
tumours is mediated in part by elevated levels of fatty
acid synthase [36]. It has been reported that some high-
grade, but not low-grade, tumours from multiple tissues
express elevated levels of MAGL (monoacylglycerol lipase)
which metabolizes glycerolipid monoacylglycerols from
neutralized lipid stores. This process liberates NEFAs (non-
esterified fatty acids) that can be converted into protumori-
genic lipid transmitters which stimulate cell migration and
tumorigenic activity [36]. Furthermore, inhibition of MAGL
activity in aggressive tumour lines impaired migration and
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Figure 2 Proposed scheme of the interaction of the Warburg effect enhanced glycolysis and regulation of gene expression
Enhanced glycolysis and regulation of gene expression may exist in both early embryos and the cells of many cancers.
Glucose metabolism through glycolysis is slowed by the expression of PKM2, which leads to a build-up of glycolytic
precursors, particularly glucose 6-phosphate, which contributes to PPP for biosynthesis. ATP is generated from other sources
such as fatty acids and amino acids. An additional role for PKM2 is via its activity as a transcription factor, where it regulates
the expression of a number of developmentally important genes, which are also implicated in the progression of cancer. CK,
creatine kinase; ETC, electron transport chain.
growth; this effect could be overcome by the addition of
exogenous sources of high fat [36]. Thismay contribute to the
trend for high triacylglycerol storage being associated with
higher levels of cancer development and progression [37].
Early embryos
One of the key features of the oocyte and early embryo of
many mammalian species is the presence of a significant store
of endogenous triacylglycerol (reviewed by [38,39]). There is
now growing evidence for the importance of triacylglycerol
metabolism for early embryos in the cow [40], pig [5] and
mouse [41], all of which have shown that pharmacological
inhibition of β-oxidation at various stages of preimplantation
development significantly reduces ongoing embryo viability.
The recent interest in fatty acid metabolism in early embryos
has been driven by the soaring global rates of obesity, such
that there are now more adults globally who are overweight
than underweight. There is growing evidence that obesity
has a negative impact on female reproductive health [42].
A number of reports have identified that the follicular
environment,which supports development of the unfertilized
oocyte, of overweight and obese women is enriched for
a number of metabolites, notably triacylglycerol [43]. The
impact of development in an enriched lipid environment is
not yet clear; however, Van Hoeck et al. [44] have recently
described in a bovinemodel that exposure to elevatedNEFAs
during oocyte development reduced blastocyst development
and viability. Crucially, embryos that originate from oocytes
matured in a high-NEFA environment do not use glucose at
the blastocyst stage, and the embryonic ‘Warbug effect’ that
we have described above is inhibited. This observation raises
the question of whether there may be value in targeting the β-
oxidation pathway in the metabolic manipulation of cancer
cells. Indeed, in a promising study, Tirado-Velez et al. [45]
recently reported that human myeloma cells are sensitive to
inhibition of fatty acid metabolism.
Parallels in regulation
In the sections above, we described some parallels and
differences in overall fuel utilization and specific substrate
depletion and production between cancer cells and early
embryos. However, there is evidence for parallels in the
underlying regulatory mechanisms. To give one example,
Christofk et al. [46] proposed a role for PK (pyruvate
kinase) in cancer cell progression. Normally, PK catalyses
the final step of glycolysis, where it dephosphorylates PEP
(phosphoenolpyruvate), forming ATP and pyruvate. There is
particular interest in the isoform PKM2, which is expressed
by all cancer cells studied to date [47]. Vander Heiden
et al. [47] proposed that PKM2 leads to an ‘alternative’
glycolysis where PEP phosphorylates the enzyme PGAM
(phosphoglycerate mutase). It is widely believed that this
occurs because PKM2 is a less active isoform of PK [46], thus
reducing the rate of formation of pyruvate. Phosphorylation
of PGAM increases its activity, leading to feedback where
PKM2 is bypassed, since removal of phosphoryl from
PEP results in the production of pyruvate. Essentially,
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this produces pyruvate from PEP without transferring
the phosphoryl group to ADP and so bypasses an ATP
production step in glycolysis, while enhancing the pathway
overall. It is therefore conceivable that a consequence of such
a strategy is increased glucose uptake and phosphorylation,
which can then be diverted into the PPP.
This possible role for PKM2 in metabolic regulation
in cancer cells is particularly relevant, since PKM2 is the
embryonic form of PK. This may partially explain the
early embryo’s preference for pyruvate as a fuel source
during early cleavage. Embryos express PKM2 (fetal exon
D, resulting in the M2 variant) similarly to tumour cells and
expression increases at the blastocyst stage [48], the time at
which the early embryo markedly increases glucose uptake
and glycolysis, yet still relies on oxidative processes for
the production of 80–90% of its ATP. Interestingly, serine
has been proposed recently to activate PKM2 [49]. This is
particularly relevant since early embryos and some cancer
cell types [50] consume significant amounts of serine.
In addition to its catalytic role, PKM2 can localize to the
nucleus where it acts as a transcription factor and is involved
in histone modification and epigenetic regulation [51]. Of
particular interest is the observation that PKM2 has been
implicated in the transcriptional regulation of Oct4, Myc,
KRAS,HIF, TFAM, SLC2A1, STAT3 and p53 [52]; all genes
that play a well-defined role in the progression of many
cancers. However, many of these genes are also required for
normal embryonic development (Figure 2).
Conclusion
On the strength of a significant body of research, there do
appear to be a number of metabolic parallels between early
embryos and cancer cells. However, it is necessary to be
cautious of over-interpretation, particularly with regard to
cancer cell metabolism. ‘Cancer’ is a broad term, and there is
wide variation between different types. Furthermore, much
of the data on cancer cell metabolism have of necessity been
derived from cancer cells in vitro; the situation may well be
different in cancer cells in vivo, where there will be complex
cell–cell and tissue–tissue interactions as well as an intricate
network of signals present in a functioning physiological
system. By contrast, the early embryo can be considered an
‘autonomous system’, with very definite and reproducible
end points.As the alteredmetabolic activity that characterizes
many tumours is recognized as an integral part of
the tumorigenic pathway, rather than a mere by-product
of cell transformation, the early embryomay represent a good
model to enhance our understanding of metabolic strategies
of ‘de-differentiated’ cells including cancer cells.
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